

Abstract

A modified protein. The modified protein comprises a protein moiety and a modified moiety. An optional PAS is linked to the N-terminus of the protein moiety, the modified moiety is directly
5 or by means of a linker linked to a cysteine residue in the protein moiety or in the optional PAS, and the cysteine residue is naturally occurring or introduced by mutation. The original activity of the modified protein is retained, and the half-life of the modified protein in vivo is also significantly improved. The modified protein involves a simple preparation process and is suitable for the development of a series of drugs for treating non-alcoholic steatohepatitis, type 2 diabetes,
10 hyperlipidemia, atherosclerosis and the like.

No Figure.